VREOFOTCPharmaceutical PreparationsFiscal year ends December 31
Vireo Growth Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$9.01+0.01 (+0.11%)
Close on Oct 19, 2026
- Market cap
- $406.23M
- P/E (TTM)
- –
- Dividend yield
- –
Vireo Growth Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cannabis | $175.80M | – | – | – | – | – | – | – | – | – | – | – | 84.0% | – |
| Non-Cannabis | $33.50M | – | – | – | $0 | – | – | – | – | – | – | – | 16.0% | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cannabis | $21.00M | – | – | – | – | – | – | – | – | – | – | – | – |
| Non-Cannabis | -$100.00K | – | – | – | – | – | – | – | – | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retail | – | $89.90M | $87.97M | $75.95M | $36.77M | $19.20M | $19.38M | $19.74M | $20.82M | $19.60M | $19.86M | $20.15M | – | – |
| Service | – | – | – | – | – | – | – | – | – | – | – | $228.97K | – | – |
| Wholesale | – | $16.30M | $16.54M | $15.70M | $11.29M | $5.30M | $5.65M | $5.42M | $4.29M | $4.49M | $4.31M | $4.53M | – | – |
By region
From the segment and revenue-disaggregation notes of Vireo Growth's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.